At 1 year, effective closure—defined as peridevice flow ≤ 5 mm on transesophageal echocardiography—was seen in 100% of patients who had a Watchman FLX successfully inserted. Implant success rate was high at 98.8%. In the study, patients were treated with 45 days of a direct oral ...
The LAA-closure with the WATCHMAN device provides an alternative to lifetime anticoagulation. We evaluated success rate and safety of WATCHMAN implantation in patients with atrial fibrillation and contraindications to oral anticoagulation due to severe bleeding. In 26 patients (72卤11 years, 8 female)...
device success (97.4% vs 96.6%), and procedural success (96.1% vs 94.6%), as well as a slightly shorter procedure duration (mean 83.0 vs 86.8 min;P< 0.001 for all).
(NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage – the area of the heart where stroke-causing blood clots commonly form. This technology, which is built upon the most studied and implanted LAAC device in the world, features a...
*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA. †Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke...
*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA. †Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke...
Indications,contraindications,warningsandinstructionsforusecanbefoundintheproductlabelingsuppliedwitheachdevice.Informationfortheuseonlyincountrieswithapplicablehealthauthorityproductregistrations WATCHMAN™临床试验 四年的随访数据证实，WATCHMAN相比于华法林在主要疗效终点，全因死亡率以及心血管死亡率上 1HolmesDRetal....
We performed an analysis of WATCHMAN procedures (January 2019 to October 2021) from the National Cardiovascular Data Registry LAAO Registry. Three-level hierarchical generalized linear models were used to assess the adjusted relatio...
All-cause death, ischemic stroke, systemic embolism, or device- or procedure-related adverse events requiring surgery or major endovascular intervention within 7 days following the procedure or by hospital discharge, whichever is later. * Based on the combined rate observed in PREVAIL(1) and CAP2...
Device implantation success rate was 100% in both groups. No device embolization, no significant peri-device leak, no tamponade, no stroke, and no access site bleeding occurred in any patient. Total hospital stay for stand-alone LAAO was comparable between groups (2 days [2–2] vs. 2 ...